Intermittent immunotherapy in patients with metastatic kidney cancer
The combination of ipilimumab/nivolumab is approved for patients as a [...]
Patient perspectives on reduced treatment schedules for immunotherapy
Immunotherapy has transformed the treatment of many cancers, including kidney [...]
ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
